The first clinical study of an oral small-molecule GLP-1 receptor agonist suggests effective glycemic control and weight loss in patients with type 2 diabetes.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Parker, J. C. et al. J. Pept. Res. 52, 398–409 (1998).
Saxena, A. R. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01391-w (2021).
Sloop, K. W. et al. Diabetes 59, 3099–3107 (2010).
Holst, J. J., Ørskov, C., Vagn-Nielsen, O. & Schwartz, T. W. FEBS Lett. 211, 169–174 (1987).
Nauck, M. A. Metabolism 103, 154031 (2020).
Nauck, M. A. & Meier, J. J. Eur. J. Endocrinol. 181, R211–R234 (2019).
Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. Mol. Metab. 46, 101102 (2020).
Davies, M. et al. J. Am. Med. Assoc. 318, 1460–1470 (2017).
Gabery, S. et al. JCI Insight 5, e133429 (2020).
Nauck, M. A., Kemmeries, G., Holst, J. J. & Meier, J. J. Diabetes 60, 1561–1565 (2011).
Meier, J. J. et al. Diabetes Care 38, 1263–1273 (2015).
Kawai, T. et al. Proc. Natl Acad. Sci. USA 117, 29959–29967 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.A.N. has been member on advisory boards or has consulted with AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk; has received grant support from AstraZeneca, Eli Lilly, Menarini/Berlin-Chemie, Merck, Sharp & Dohme, and NovoNordisk; and has served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk. J.J.M. has received consulting and speaker honoraria from AstraZeneca, Eli Lilly, Merck, Sharp & Dohme, Novo Nordisk, Sanofi and Servier; and has received research support from Boehringer-Ingelheim, Eli Lilly &, Merck, Sharp & Dohme, Novo Nordisk, and Sanofi.
Rights and permissions
About this article
Cite this article
Nauck, M.A., Quast, D.R. & Meier, J.J. Another milestone in the evolution of GLP-1-based diabetes therapies. Nat Med 27, 952–953 (2021). https://doi.org/10.1038/s41591-021-01394-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-021-01394-7